A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: Application to pharmacokinetic studies

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 5, 2013, Pages 1104-1110

  He, Jie ^a   Gao, Song ^a   Hu, Ming ^a   Chow, Diana S L ^a   Tam, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

Author keywords

Biological samples; Polymyxin; UPLC MS MS

Indexed keywords

ACETONITRILE; CARBUTAMIDE; FORMIC ACID; ISOLEUCINE; POLYMYXIN B; POLYMYXIN B1; POLYMYXIN B2; POLYMYXIN B3; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG; WATER;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; EPITHELIAL LINING FLUID; EPITHELIUM CELL; FEMALE; IONIZATION; LIMIT OF QUANTITATION; MOUSE; MULTIPLE REACTION MONITORING; NONHUMAN; PRECIPITATION; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

ANIMALS; ANTI-BACTERIAL AGENTS; BODY FLUIDS; CHROMATOGRAPHY, LIQUID; FEMALE; MICE; POLYMYXIN B; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84877129855     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks536     Document Type: Article

References (16)

1. Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.
2. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006; 12: 315-21.
3. Pastewski AA, Caruso P, Parris AR et al. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann Pharmacother 2008; 42: 1177-87.
4. Bratu S, Quale J, Cebular S et al. Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B. Eur J Clin Microbiol Infect Dis 2005; 24: 196-201.
5. Shoji J, Hinoo H, Wakisaka Y et al. Isolation of two new polymyxin group antibiotics. (Studies on antibiotics from the genus Bacillus. XX). J Antibiot (Tokyo) 1977; 30: 1029-34.
6. Orwa JA, Govaerts C, Busson R et al. Isolation and structural characterization of polymyxin B components. J Chromatogr A 2001; 912: 369-73.
7. He J, Ledesma KR, Lam WY et al. Variability of polymyxin B major components in commercial formulations. Int J Antimicrob Agents 2010; 35: 308-10.
8. Simon HJ, Yin EJ. Microbioassay of antimicrobial agents. Appl Microbiol 1970; 19: 573-9.
9. He J, Figueroa DA, Lim TP et al. Stability of polymyxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 258C. Am J Health Syst Pharm 2010; 67: 1191-4.
10. Orwa JA, Van Gerven A, Roets E et al. Liquid chromatography of polymyxin B sulphate. J Chromatogr A 2000; 870: 237-43.
11. Cheng C, Liu S, Xiao D et al. LC-MS/MS method development and validation for the determination of polymyxins and vancomycin in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 2831-8.
12. Yuan Z, Tam VH. Polymyxin B: a new strategy for multidrugresistant Gram-negative organisms. Expert Opin Investig Drugs 2008; 17: 661-8.
13. Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother 2008; 52: 24-36.
14. Tam VH, Cao H, Ledesma KR et al. In vitro potency of various polymyxin B components. Antimicrob Agents Chemother 2011; 55: 4490-1.
15. Furtado GH, d'Azevedo PA, Santos AF et al. Intravenous polymyxin B for the treatment of nosocomial pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2007; 30: 315-9.
16. Holloway KP, Rouphael NG, Wells JB et al. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit. Ann Pharmacother 2006; 40: 1939-45.